

## **Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2**

Rajat Ujjainiya<sup>1,2#</sup>, Akansha Tyagi<sup>3#</sup>, Viren Sardana<sup>1,2#</sup>, Salwa Naushin<sup>1,2</sup>, Nitin Bhatheja<sup>1</sup>, Kartik Kumar<sup>1</sup>, Joydeb Barman<sup>1</sup>, Satyartha Prakash<sup>1</sup>, Rintu Kutum<sup>1,2</sup>, Menka Loomba<sup>3</sup>, Yukti Khanna<sup>3</sup>, Chestha Walecha<sup>3</sup>, Rizwan Ahmed<sup>3</sup>, Ashutosh Yadav<sup>4</sup>, Archana Bajaj<sup>11</sup>, Gaurav Malik<sup>11</sup>, Sahar Qureshi<sup>10</sup>, Swati Waghdhare<sup>4</sup>, Samreen Siddiqui<sup>4</sup>, Kamal Krishan Trehan<sup>11</sup>, Manju Mani<sup>10</sup>, Rajiv Dang<sup>9</sup>, Poonam Das<sup>6</sup>, Pankaj Dougall<sup>7</sup>, Monica Mahajan<sup>8</sup>, Sandeep Buddhiraja<sup>5</sup>, Anurag Agrawal<sup>1,2</sup>, Debasis Dash<sup>1,2\*</sup>, Sujeet Jha<sup>4\*</sup>, Shantanu Sengupta<sup>1,2\*</sup>

<sup>1</sup>CSIR-Institute of Genomics and Integrative Biology, New Delhi

<sup>2</sup>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh

<sup>3</sup>Department of Clinical Research Max Superspeciality Hospital, Saket, New Delhi

<sup>4</sup>Institute of Endocrinology, Diabetes, and Metabolism, New Delhi

<sup>5</sup>Department of Internal Medicine, Max Superspeciality Hospital, Saket, New Delhi

<sup>6</sup>Institute of Laboratory Medicine & Transfusion Services. Max Hospital, Saket, New Delhi

<sup>7</sup>Max Hospital, Saket, New Delhi

<sup>8</sup>Max Hospital Panchsheel, New Delhi

<sup>9</sup>Max Hospital, Gurgaon, New Delhi

<sup>10</sup>Max Smart Super Speciality Hospital, New Delhi

<sup>11</sup>Max Hospital Shalimar Bagh, New Delhi

# Equal contribution

\* Corresponding authors

## Abstract

The Oxford-Astra Zeneca COVID 19 vaccine (AZD1222 or ChAdOx1) is an important part of the global vaccine roll-out against SARS-CoV-2, and a locally manufactured version (Covishield by Serum Institute, Pune, India) is the most commonly used vaccine in India. The vaccination program started in January 2021 and here we report effectiveness of the first dose of Covishield in generating antibody response and its kinetics. We further report differences in the quantitative antibody response amongst individuals who had pre-existing antibodies to SARS CoV2 and those who did not. In a group of 135 healthcare workers administered Covishield, we measured antibodies to SARS-CoV-2 directed against the spike protein (S-antigen) using Elecsys Anti-SARS-CoV-2 S quantitative antibody detection kit (Roche Diagnostics) at days 0, 7, 14, and 28. In 44 subjects (32.5%) who had already developed antibodies to SARS-CoV-2 at day 0 (before immunization), it was observed that antibody response was significantly higher at each time point, with the maximum increase seen between days 0 and 7. In contrast the sero-negative group (n=91) started developing antibody response only after 14 days or later. Three sero-negative individuals did not develop any antibody response even at day 28 of vaccination. It is noted that median antibody response at 28 days in seronegative subjects was similar to that of seropositive subjects at baseline (day 0) and was on a rising trajectory. Our data suggests that ChAdOx1 is highly immunogenic, particularly so where previous SARS CoV2 antibody-response is established. Given the high background seropositivity in India, this may be useful in determining optimal timing of the second dose during mass immunization within the constraints of vaccine supply and administration.

## Keywords:

Covid 19, Vaccine, Antibody Response, SARS-CoV-2, Immunity, Public Health

## Introduction

As the covid pandemic swept global economies last year, tireless efforts to develop vaccines against SARS-CoV-2 were underway and a few vaccines have already been developed in record time to control the spread of SARS-CoV-2 infection worldwide. To protect at the earliest the vulnerable and exposed from acquiring the dreaded infection; frontline healthcare workers, sanitization staff, elderly with co-morbidities etc. was at high priority of governments around the world. India began its ambitious vaccination program from January 2021 after approval of two candidate vaccines; one being Covishield (AZD1222 technology acquired from co-development of Oxford University and AstraZeneca, by Serum Institute of India, Pune) and the other being Covaxin (Bharat Biotech developed vaccine using Vero cell lines in collaboration with ICMR, India) after an emergency restricted use approval by the Directorate General of Health Services (DGHS).<sup>1</sup> Both vaccines had peer reviewed studies published demonstrating the immunogenicity after extensive clinical trials, though Covaxin was to undergo phase III trials, it was given an approval for restricted use under these emergency conditions.<sup>2-4</sup>

With the introduction and approval of vaccines, it became imperative to understand the immunogenicity and efficacy in antibody development. In an earlier published preprint, a similar study was carried out to understand the antibody response after receiving the Pfizer and Modern Vaccine in New York and Paris. They observed a significant difference in antibody response amongst people who already had pre-existing immunity to the disease in comparison to those who did not.<sup>5 6</sup> Another study from Maryland utilizing an IgG ELISA based assay to spike protein observed similar response type albeit in healthcare workers.<sup>6 7</sup>

This, as one of the early studies from the country and regions utilizing Covishield vaccine aimed to understand the kinetics of antibody development in health-care workforce who stand as one of the most vulnerable in our fight against this pandemic. A large percentage of the health-care workforce had already been infected with SARS-CoV-2 and had developed antibodies against the virus. Thus, we also checked if being sero-positive leads to measurable differences in antibody levels compared to sero negative individuals after the administration of the first dose of vaccine.

The present study was carried at a tertiary level healthcare chain in Delhi, India where Covishield was administered to all personnel. Covishield is an in-activated viral vaccine and utilizes the S-antigen to generate an antibody response. It had to be given in two doses spread 4-6 weeks apart to attain immunogenic levels, though it was observed through observational studies as mentioned in factsheet that the response is attainable even when the two doses are given 12 weeks apart rather being more effective at 12 weeks interval.

## **Materials and Methodology**

The study was approved by the ethics committee of Max Hospital, New Delhi and CSIR-IGIB, New Delhi. Subjects were enrolled under the study who were to receive the Covishield vaccine under a voluntary enrolment process to monitor their antibody response before getting the vaccine followed by measurement at various time intervals. Herein, we analysed data of 135 subjects who had provided their samples on the day of receiving the first dose and on the 28<sup>th</sup> day i.e., the day they receive their second dose as per standard protocol. Of these 135 subjects 82 and 69 also gave samples at 7 and 14 days, respectively.

Blood samples (6 ml) were collected in EDTA vials from each participant and antibodies to SARS-CoV-2 directed against the spike protein (S-antigen) were assayed using Elecsys Anti-SARS-CoV-2 S quantitative antibody detection kit (Roche Diagnostics) according to the manufacturer's protocol. Antibody levels >0.8 U/ml were sero-positive

Friedman's ANOVA was utilized to assess difference in antibody response on serial follow up for individuals who gave samples at all data points. Non-Parametric Mann-Whitney test was utilized to assess two groups i.e., those that had pre-existing antibodies and those who did not for time specific significant differences if any after

assessment of data distribution. Statistical analysis was carried out with visualization in R version 3.6.1 and MS-Excel 2016 and OriginPro V2021.

### **Role of the funding source**

The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### **Results and Discussion**

This study was done in 135 subjects for whom we had both baseline (pre-vaccination) and 28 day post vaccination data. Of these 135 subjects, 44 (32.5%) had already developed antibodies to SARS-CoV-2. These personnel were then assigned to two groups, one who had developed antibodies prior to vaccination and the other who had not. In addition to baseline and 28 days post vaccination, 53 subjects also gave their samples at 7 days and 14 days post vaccination i.e. data for these individuals are available at all 4 time points. It was observed that the antibody response at 7 days in the people who already had antibodies was significantly higher than the individuals who did not had antibodies prior to vaccination ( $p < 0.0001$ ); rather, greater than ninety percent of naïve individuals didn't develop any measurable response at all at day 7. (Figure 1). This was corroborated at day 14 when both groups had started developing antibodies though the difference was still significant amongst them ( $p < 0.0001$ ). On day 28, before the second dose of vaccination, most of the individuals except three amongst sero-negative group had measurable antibody response and the difference was greater than 500 times in median antibody titre levels amongst two groups when compared for 53 individuals who gave samples at all 4 time points and 200 times when compared for all 135 individuals. There was significant response when compared to baseline at day 14 and day 28 of vaccination in both groups for 53 individuals on repeated measure ANOVA. Though, the antibody response needs to be monitored for a longer term for evaluation on sustenance of this response and demonstratable difference if any amongst the two groups.




Figure 1: Antibody titres in U/ml at Day 0, 7, 14 and 28 for the two groups; sero-positive on day 0 before vaccination (red) and sero-negative on day 0 before vaccination (blue). A) Data for all individuals available in the study at 4 time points. B) Data for individuals who gave their samples at all 4 time points.

Oxford/AstraZeneca vaccine which is being produced as Covishield in India had acceptable rather a better response when two doses are given 12 weeks apart.<sup>8 9</sup> This has led to certainly a confusion not only amongst healthcare workforce but also researchers worldwide who had observed similar outcomes with other vaccine candidates too. As the study in NY, Maryland and Paris concluded single dose of Pfizer and Moderna vaccine to be effective in people with pre-existing immunity in argument of more doses being made available to target a larger population seeing the limited supply of the vaccine,<sup>5 7</sup> there were reports who were not in agreement with them. It was explicitly stated that the vaccine efficiency of Pfizer improved substantially after second dose<sup>10</sup> and a single dose was not good enough from a large scale study from Israel.<sup>11</sup> Dr Livingston at JAMA has expressed some important concerns in view of delaying the second dose which should be taken seriously in context of current vaccination program and pandemic spread.<sup>12</sup> The vaccination dosing has been deliberately kept short to elicit brisk immune response for the pandemic could be brought under control and if the majority of population doesn't get their second dose, the purpose of this vaccine drive gets defeated.

While there is still a standing debate going on between the timing of second dose, and though we agree with Dr Livingston's opinion, the vaccine being administered in India is different and has been tested at different dosing intervals.<sup>13</sup> It has demonstrated considerable efficacy response after a single dose, and the effect is likely to be even higher amongst individuals with pre-existing immunity. Thus this data could be utilized to design an effective vaccine strategy where vaccine could be prioritized based on sero-prevalence studies. Our data supports safely delaying the second dose in recipient groups with high sero-positivity. This could be adopted as a universal strategy, given that the first dose seems to give adequate protection lasting for about three months in other studies, or could be one part of a dual strategy where high-risk or vulnerable populations receive the second dose earlier, while normal-risk subjects have a delayed second dose.

## Conclusion

This work aimed to study pre-existing antibody status and antibody kinetics upon vaccination in healthcare workers being given Covishield before the second dose. We could observe a significant difference in antibody response in personnel who already had pre-existing antibodies in comparison to those who did not. This work could help generate useful policy changes for having the second dose at later time points for selected individuals.

## Funding

Council of Scientific and Industrial Research, India

## Conflict of Interest

Authors declare no competing interests

## Acknowledgment

SSG would like to acknowledge CSIR grant for this work. SSG would like to acknowledge Manish Chowdhary, Yasmeen Khan and Preeti Subramani for sample analysis. SJ, SSG and DD would like to acknowledge all participants of the study.

## References

1. Covid-19: Indian health officials defend approval of vaccine. *BMJ* 2021;372:n52. doi: 10.1136/bmj.n52
2. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet* 2020;396(10249):467-78. doi: 10.1016/S0140-6736(20)31604-4
3. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet* 2020;396(10267):1979-93. doi: 10.1016/S0140-6736(20)32466-1
4. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *The Lancet Infectious Diseases* doi: 10.1016/S1473-3099(20)30942-7
5. Krammer F, Srivastava K, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. *medRxiv* 2021:2021.01.29.21250653. doi: 10.1101/2021.01.29.21250653
6. Wise J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. *BMJ* 2021;372:n308. doi: 10.1136/bmj.n308
7. Saadat S, Rikhtegaran-Tehrani Z, Logue J, et al. Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. *medRxiv* 2021:2021.01.30.21250843. doi: 10.1101/2021.01.30.21250843
8. Wise J. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval. *BMJ* 2021;372:n326. doi: 10.1136/bmj.n326
9. Voysey M CS, Madhi S, et al. . Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1nCoV-19 (AZD1222) vaccine. Available at SSRN: <https://ssrn.com/abstract=3777268>. 2021

10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* 2020;383(27):2603-15. doi: 10.1056/NEJMoa2034577
11. Mahase E. Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected. *BMJ* 2021;372:n217. doi: 10.1136/bmj.n217
12. Livingston EH. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines. *JAMA* 2021 doi: 10.1001/jama.2021.1375
13. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet* 2021 doi: [https://doi.org/10.1016/S0140-6736\(21\)00432-3](https://doi.org/10.1016/S0140-6736(21)00432-3)